Business Wire

Technology Innovation Institute Announces Launch of NOOR, the World’s Largest Arabic NLP Model

Share

Technology Innovation Institute (TII), a global research center and applied research pillar of Abu Dhabi’s Advanced Technology Research Council, today announced the launch of NOOR, the world’s largest Arabic natural language processing (NLP) model to date.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005085/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Noor, the world's largest Arabic NLP Model - AI Cross-Center Unit, Technology Innovation Institute (Photo: AETOSWire)

TII’s team of advanced researchers and Artificial Intelligence (AI) specialists, has joined forces with LightOn, a technology company that unlocks extreme-scale machine intelligence for businesses, to transform the Arabic NLP model. The NOOR model has the capability to carry out tasks beyond the domain of language - offering end-to-end pipeline high quality data, including crawling, filtering, and curation at scale. The model facilitates extreme-scale distributed training and serving – to deliver applications with efficient inference and model specialization.

Dr. Ray O. Johnson, CEO, TII and ASPIRE, said: “With this development, we are well on track to enhance our research capabilities and credentials as well as elevate the status of Abu Dhabi and the UAE as a serious research ecosystem. Our expert teams have demonstrated yet again that this region can achieve breakthrough R&D outcomes to impact the world.”

Dr. Ebtesam Almazrouei, Director, AI Cross-Center Unit, TII, said: “Large language models have taken the world of natural language processing by storm, and we are proud to introduce this cutting-edge model with 10 billion parameters - the world’s largest Arabic NLP model. The uniquely large Arabic dataset collected to train the model is the result of months of work that included curating, scrapping, and filtering of varied sources. A special thank you to the entire team that worked on this project to make NOOR the go-to exploration model in Arabic for academicians and businesses everywhere.”

Speaking on the launch, Prof. Mérouane Debbah, Chief Researcher, Digital Science Research Center and AI Cross-Center Unit, TII, said: “With NOOR, TII has expanded the scope of the modern standard Arabic model by leveraging know-how in large language models to build cross-disciplinary, cutting-edge expertise in this new generation of AI research.”

To curate the world’s largest high-quality cross-domain Arabic datasets, NOOR’s unique dataset of more than 30 billion words combines web data with books, poetry, news articles, and technical information to significantly widen the applicability of the model.

Dr. Ebtesam Almazrouei said the NOOR model is based on the popular Transformer architecture. As a decoder-only model, similar in structure to GPT-3, it is programmed to tackle generative tasks with architecture upgraded to reflect the latest developments in the world of machine learning, including improvements such as better positional embeddings. To help ensure quality at scale in the NOOR dataset, the TII team designed an automated filtering pipeline based on machine learning techniques. These tools identify text like quality references and safeguard the model from exposure to spam content.

Leveraging state-of-the-art 3D parallelism, NOOR was trained on a High-Performance Computing resource with 128 A100 GPUs, allowing for the distribution of computations and ensuring efficient use of the available hardware resources.

The Director of the AI Cross-Center Unit noted that this was only the first step in the Unit’s efforts to contribute to the wider UAE Strategy for Artificial Intelligence.

Named for the Arabic word "light", the model has been so called to establish the correlation of the Arabic language model to enlightening the mind.

About Technology Innovation Institute (TII)

For more information, visit www.tii.ae

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Technology Innovation Institute
Sneha Sivanand, sneha.sivanand@tii.ae

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye